Retention of Sample-USFDA [GxP / QC / QA]

posted by Rajdeep  – New Delhi, India, 2010-10-19 14:25 (5718 d 22:25 ago) – Posting: # 6062
Views: 8,282

Dear All

Need your feedback on the regulatory aspect.

What if the sponsor fails to provide the information about the in-vitro release test data for calculating retention quantity for USFDA BE studies and also fails to provide the upper limit of [300 units (test/reference each)] solid dosage-formulation?

Can a CRO retain the balance samples as suggested by the sponsor?
What if the CRO has raised the concern but the sponsor instructs to retain the balance IPs. Is the step okay? Which body (CRO/sponsor)will be responsible for the same? And what will be the regulatory concern?
:ponder:


Edit: Category changed. [Helmut]

Best regards
Rajdeep Mukherjee
Protocol Developer

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
142 visitors (0 registered, 142 guests [including 12 identified bots]).
Forum time: 12:51 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5